PANCHSHEEL.BO · BSE
PANCHSHEEL ORGANICS LTD.
₹106.2
-0.42% (-₹0.45)
Prev. close
₹106.65
Volume
1,953
As of
BSE · may be slightly delayed · 16:00 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About PANCHSHEEL ORGANICS LTD.
Panchsheel Organics Limited engages in the manufacture and trade of bulk drugs and intermediates in India and internationally. The company manufactures and exports active pharma ingredients (API), human and veterinary intermediates and finished formulations, specialty chemicals, nutraceuticals, vitamins hormones, agri biotech range, aqua culture, dehydrated culture media, finished formulations, and steroids, etc. It also provides a range of products in various categories, such as cardiovascular, neuropsychiatry, anti-fungal, fluoroquinolones, antiallergic, anti-inflammatory, gastrointestinal, osteoporosis, erectile dysfunction, and others. Panchsheel Organics Limited was incorporated in 1989 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Kishore Abhaychand Turakhia
Headquarters
Mumbai
Employees
191
Website
panchsheelorganics.comExchange
View on BSE ↗Key stats
Market cap
₹110.76 Cr
P/E ratio (TTM)
13.6
Dividend yield
2.92%
EPS (TTM)
₹7.83
Beta (1Y · daily vs NIFTY 50)
1.28
Beta (5Y · monthly vs NIFTY 50)
0.73
Shares float
75.61 L
EPS · quarter ended Jun 2026
₹1.76
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.5% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹49.50 Cr | ₹69.03 Cr | ₹102.68 Cr | ₹105.20 Cr | ₹107.09 Cr | ₹106.69 Cr | |
| EBITDA | ₹8.84 Cr | ₹12.93 Cr | ₹20.83 Cr | ₹21.22 Cr | ₹20.37 Cr | ₹16.91 Cr |
| ₹5.01 Cr | ₹8.36 Cr | ₹14.07 Cr | ₹14.11 Cr | ₹13.79 Cr | ₹10.83 Cr | |
| Diluted EPS | ₹9.98 | ₹8.33 | ₹11.94 | ₹10.71 | ₹10.47 | ₹8.22 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹122.68 Cr | ₹159.05 Cr | ₹163.28 Cr | ₹171.93 Cr | |
| — | — | ₹5.58 Cr | ₹6.31 Cr | ₹5.44 Cr | ₹5.65 Cr | |
| Stockholders' equity | — | — | ₹96.06 Cr | ₹125.03 Cr | ₹133.86 Cr | ₹140.83 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹4.21 L | ₹9.57 Cr | ₹3.83 Cr | ₹10.31 Cr | |
| Investing cash flow | — | — | ₹-34.37 Cr | ₹-7.22 Cr | ₹-16.33 Cr | ₹-6.70 Cr |
| — | — | ₹35.82 Cr | ₹16.03 Cr | ₹-5.20 Cr | ₹-4.25 Cr | |
| Capital expenditure | — | — | ₹-3.95 Cr | ₹-9.89 Cr | ₹-15.56 Cr | ₹-6.91 Cr |
| End cash position | — | — | ₹3.46 Cr | ₹21.85 Cr | ₹4.15 Cr | ₹3.52 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| PANCHSHEEL ORGANICS LTD. | ₹113.82 Cr | ₹109.6 | 14.0 | 0.81 | 7.7% | 0.04 | -0.4% | -23.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 23
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.